<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Lenalidomide is an immunomodulator used to treat 5q-<z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo>, and <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We describe a 55-year-old male who was started on lenalidomide 10â€‰mg daily for 21 days followed by 7 days off therapy for the treatment of early stage post-<z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Following initiation of lenalidomide, the patient was noted to have an asymptomatic increase in unconjugated <z:chebi fb="0" ids="16990">bilirubin</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Alkaline phosphatase, <z:chebi fb="0" ids="29995">aspartate</z:chebi> transaminase, and alanine aminotransferase were <z:mpath ids='MPATH_458'>normal</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>During the 7 days off of lenalidomide, <z:chebi fb="0" ids="16990">bilirubin</z:chebi> began to trend down </plain></SENT>
<SENT sid="5" pm="."><plain>Re-challenge with lenalidomide in subsequent cycles results in an asymptomatic elevation in unconjugated <z:chebi fb="0" ids="16990">bilirubin</z:chebi> followed by improvement during the 7-day lenalidomide-free period </plain></SENT>
<SENT sid="6" pm="."><plain>The patient is a heterozygote for the TA7 allele which can decrease expression of <z:chebi fb="0" ids="17659">uridine diphosphate</z:chebi> glycuronosyl transferase 1A1, the enzyme responsible for conjugation of <z:chebi fb="0" ids="16990">bilirubin</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>Therapy with lenalidomide may have unmasked <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> in the patient </plain></SENT>
</text></document>